Quantum-Si Q1 revenue falls, net loss widens on Proteus spending

Quantum-Si

07/05/2026 21:45

Overview

Proteomics technology firm's Q1 revenue declined yr/yr as company prioritizes Proteus platform launch

Net loss widened to $21.7 mln in Q1 as R&D spending increased for Proteus development

Company reiterated 2026 guidance, expects revenue to be impacted by Proteus launch preparations

Outlook

Quantum-Si sees 2026 revenue at approximately $1.0 mln

Company expects 2026 adjusted total operating expenses of $98.0 mln or less

Quantum-Si anticipates 2026 total cash usage of $93.0 mln or less

Result Drivers

PROTEUS DEVELOPMENT - Increased R&D spending and focus on achieving development milestones for Proteus platform drove results

COMMERCIAL LAUNCH PREPARATIONS - Revenue impacted by strategic actions ahead of Proteus launch, including embedding upgrade credits and customer purchase delays

COST CONTROLS - Lower selling, general and administrative expenses due to continued tight cost controls

Company press release: ID:nBwCWm58a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$258,000
Q1 EPS
-$0.10
Q1 Net Income
-$21.67 mln
Q1 Operating Expenses
$24.13 mln
Q1 Operating Income
-$24.05 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Quantum-Si Inc is $2.50, about 142.7% above its May 6 closing price of $1.03

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)